RxDoctor Payments DataLook up a doctor →

Mario Bustos Rodriguez, MD

Endocrinology, Diabetes & Metabolism · Tulsa, OKNPI 1700265584

Payments from drug & device makers

$18,742in general payments, 2019–2025

Across 664 payments — averaging $28.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Dexcom, Inc.$3K
  • Abbott$3K
  • AstraZeneca$2K
  • Novo Nordisk$2K
  • Boehringer Ingelheim$1K
  • Lilly USA, LLC$1K
  • plus $6K from 32 others

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$18,742 in reported general payments places this provider in the 80th percentile of 61 endocrinology, diabetes & metabolism providers in Oklahoma.

See all endocrinology, diabetes & metabolism providers in Oklahoma

Medicare billing

Part B allowed, 2024
$70,134
Medicare patients
316
Services billed
754

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other endocrinology, diabetes & metabolism in Tulsa

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →